Ropes & Gray Advises Amylyx Pharmaceuticals in Acquisition of Phase 3-Ready Asset From Eiger BioPharmaceuticals
July 12, 2024
July 12, 2024
BOSTON, Massachusetts, July 12 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray represented Amylyx Pharmaceuticals in acquiring a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide, from Eiger BioPharmaceuticals that is ready for Phase 3 trials for post-bariatric hypoglycemia (PBH), a common complication of bariatric surgery, and congenital hyperinsulinism (HI).
The transaction was announced on July 10. Under the agre . . .
Ropes & Gray represented Amylyx Pharmaceuticals in acquiring a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, avexitide, from Eiger BioPharmaceuticals that is ready for Phase 3 trials for post-bariatric hypoglycemia (PBH), a common complication of bariatric surgery, and congenital hyperinsulinism (HI).
The transaction was announced on July 10. Under the agre . . .